Zepbound vs Wegovy: A two horse race

from BioSpace · host BioSpace

Last week, the FDA approved Eli Lilly's obesity drug Zepbound, creating an anticipated intense competition between it and Novo Nordisk's Wegovy. BioSpace's Greg Slabodkin, Tyler Patchen and Lori Ellis discuss the weight loss race and the future of this drug class. Plus, a quick recap on Valneva, the FDA's first Chikungunya vaccine approval.

Episode metadata supplied by the publisher feed · Published Nov 15, 2023

Embed this episode

Attribution link and audio player

NOW PLAYING

Zepbound vs Wegovy: A two horse race

0:00 14:24

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of BioSpace?

This episode is 14 minutes long.

When was this BioSpace episode published?

This episode was published on November 15, 2023.

Can I download this BioSpace episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!